Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

Delayed Quote. Delayed  - 09/29 10:00:00 pm
0.8899 USD   +1.13%
09/06 AVEO PHARMACEUT : to Present at the 18th Annual Rodman & Renshaw Glo..
08/15 AVEO PHARMACEUT : Initiates the Evaluation of Tivozanib in Combinati..
08/04 AVEO PHARMACEUT : reports 2Q loss
News SummaryMost relevantAll newsSector news 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
06/25/2013 | 11:25pm CEST

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
Fax: 302-654-7530

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
09/12 AVEO PHARMACEUTICALS INC : Other Events (form 8-K)
09/06 AVEO PHARMACEUTICALS : to Present at the 18th Annual Rodman & Renshaw Global Inv..
08/15 AVEO PHARMACEUTICALS : Initiates the Evaluation of Tivozanib in Combination with..
08/04 AVEO PHARMACEUTICALS : reports 2Q loss
08/04 AVEO PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financ..
08/04 AVEO ONCOLOGY : Reports Second Quarter 2016 Financial Results and Provides Busin..
08/04 AVEO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditi..
06/15 AVEO PHARMACEUTICALS INC : Termination of a Material Definitive Agreement, Regul..
06/15 AVEO PHARMACEUTICALS : to Present at the 2016 JMP Securities Life Science Confer..
06/02 AVEO PHARMACEUTICALS : Patent Issued for Reconstituted Human Breast Tumor Model ..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/15 AVEO initiates early-stage study of tivozanib and Opdivo in kidney cancer
08/04 AVEO Pharmaceuticals beats by $0.01, beats on revenue
05/26 AVEO's late-stage study of lead product candidate tivozanib in difficult-to-t..
05/18 BIOTECH FORUM DAILY DIGEST : Will Anacor Kick Off M&A Wave? Spotlight On 'Lotter..
05/13 AVEO secures private $17M capital raise
Financials ($)
Sales 2016 1,60 M
EBIT 2016 -31,0 M
Net income 2016 -34,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 42,2x
Capi. / Sales 2017 8,12x
Capitalization 67,5 M
More Financials
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 2
Average target price 2,38 $
Spread / Average Target 167%
Consensus details
EPS Revisions
More Estimates Revisions
Michael P. Bailey President, Chief Executive Officer & Director
Keith S. Ehrlich Chief Financial Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
More Results